Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of personalized medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Aug 31, 2020

Dr. Tim Rodell, Chief Executive Officer, Aethlon Medical brings us up to speed on the work at Aethlon in developing immunotherapeutic technologies using their Hemopurifier to clear a virus as well as exosomes in patients with cancer as blood flows through the nanofibers of the Hemopurifier cartridge. With more recent...


Aug 31, 2020

Dr. Tim Rodell, Chief Executive Officer, Aethlon Medical brings us up to speed on the work at Aethlon in developing immunotherapeutic technologies using their Hemopurifier to clear a virus as well as exosomes in patients with cancer as blood flows through the nanofibers of the Hemopurifier cartridge. With more recent...


Aug 5, 2020

Apostolos Stathopoulos, CEO, ERC-Belgium talks about using immunotherapy to treat glioblastoma, the most malignant of all gliomas or brain cancers.  ERC's therapy, which stimulates the patient's immune system to mount an immune response against the tumor cells, has demonstrated a clinically meaningful survival benefit...


Aug 5, 2020

Apostolos Stathopoulos, CEO, ERC-Belgium talks about using immunotherapy to treat glioblastoma, the most malignant of all gliomas or brain cancers.  ERC's therapy, which stimulates the patient's immune system to mount an immune response against the tumor cells, has demonstrated a clinically meaningful survival benefit...


Jul 22, 2020

Jens Hennecke, Chief Business Officer, SOTIO explains how this biotech company is developing the next generation of immunotherapies with a focus on a new compound called SO-C101 based on the cytokine IL-15, the key cytokine that activates T-cells and NK cells. In clinical trials, this drug, a modified IL-15 does not...